WHAT IS SEMAGLUTIDE?

Semaglutide as a GLP-1 Agonist

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, was first introduced in 2017 under the brand name Ozempic. Initially approved for the management of Type 2 diabetes in adults, it has since been recognized for its effectiveness as a once-weekly injectable medication. In subsequent years, the FDA expanded its approval to include Wegovy, a formulation specifically designed to aid in weight management.

Comprehensive Uses & Benefits

Semaglutide is a vital tool in managing blood glucose levels for adults with Type 2 diabetes. Beyond its primary use, it also plays a crucial role in reducing the risk of serious cardiovascular events, including heart attacks and strokes, in individuals who have concurrent Type 2 diabetes and heart disease. This dual functionality highlights Semaglutide's significant impact on long-term health outcomes.

Mechanism of Action: How Semaglutide Works

Semaglutide belongs to a class of medications known as GLP-1 agonists, which are designed to mimic the effects of the gut hormone GLP-1. This mechanism not only helps lower blood glucose levels but also enhances the sensation of fullness, helping patients maintain a longer period of satiety. This unique action makes Semaglutide an effective option for both diabetes management and weight control.

Administration, Efficacy, & Comprehensive Applications

Administered as a once-weekly injectable, Semaglutide is distinguished by its long-acting efficacy, making it a convenient and sustained therapeutic option compared to medications requiring more frequent dosing.
Semaglutide is approved for long-term weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or with a BMI of 27 kg/m² or greater accompanied by a weight-related condition such as high blood pressure, Type 2 diabetes, or high cholesterol. Additionally, it is approved for use in children aged 12 and older who have a baseline BMI at the 95th percentile or higher.
Semaglutide also plays a critical role in reducing the risk of heart attack, stroke, and death due to heart complications in adults with heart disease and a larger body size.

SEMAGLUTIDE = TYPE OF INSULIN?

Semaglutide is not a form of insulin, nor is it intended as a substitute for insulin. However, it does stimulate the pancreas to release insulin in response to the presence of glucose, such as after a meal. This action is reliant on the body's own insulin production, meaning that Semaglutide is not suitable for individuals whose pancreas is unable to produce insulin, as in the case of Type 1 diabetes.

HOW DOES SEMAGLUTIDE CAUSE WEIGHTLOSS?

Semaglutide aids in weight loss by mimicking GLP-1, an incretin hormone involved in appetite regulation and digestion. It works through several mechanisms:

Slowing Gastric Emptying
Targeting Appetite Centers in the Brain
Reducing Food Cravings

While some effects, like slowed gastric emptying, may diminish over time, others, such as appetite suppression, persist only while using the medication.

GLP-1 agonists like Semaglutide primarily control blood glucose but also contribute to weight loss by slowing stomach emptying, enhancing fullness, and affecting brain regions that control appetite. By imitating GLP-1, Semaglutide helps reduce calorie intake, leading to weight loss.

SEMAGLUTIDE = STIMULANT?

Semaglutide is not a stimulant. Unlike other weight loss medications, such as phentermine, which exert stimulating effects to suppress appetite, Semaglutide operates through a different mechanism to promote weight loss. It works by mimicking the effects of the GLP-1 hormone, helping to regulate appetite and food intake without the need for stimulation.

HOW LONG DOES IT TAKE TO LOSE WEIGHT ON SEMAGLUTIDE?

Reaching the target dose of Semaglutide can take a few months, as the dosage is gradually increased to manage potential side effects. During this period, some weight loss may occur, with the amount varying based on your Semaglutide dose.

For Type 2 diabetes, the initial Semaglutide dose is 0.25 mg once weekly for 4 weeks. This introductory dose typically does not significantly affect blood glucose levels or weight; rather, it helps your body acclimate to the medication. After this, the dose is increased to 0.5 mg once weekly.

Clinical trials have shown that individuals taking the 0.5 mg dose lost approximately 8 pounds over 30 weeks. For some, this dose may not sufficiently control blood glucose levels, necessitating further dose increases at 4-week intervals, up to a maximum of 2 mg weekly.

Generally, greater weight loss and improved blood glucose control are observed with higher doses of Semaglutide. In a 40-week study, participants on the 1 mg dose lost an average of 13 pounds, while those on the 2 mg dose lost an average of 15 pounds.

For weight management, Semaglutide is prescribed at a higher target dose of 2.4 mg once weekly. During the first 20 weeks (approximately 5 months) of treatment in clinical trials, participants lost an average of 10% of their starting body weight. An additional 8% weight loss was observed over the following 48 weeks (around 11 months).

**It is important to note that for optimal results, Semaglutide should be used in conjunction with lifestyle changes, such as a balanced diet and regular physical activity.**

WHO SHOULD TAKE SEMAGLUTIDE?

Before starting Semaglutide for weight loss, it is essential to discuss the potential benefits and risks with your healthcare provider. Semaglutide is not suitable for everyone, and its use requires a long-term commitment, as discontinuing the medication may lead to rebound weight gain.

For weight loss, Semaglutide has been studied in specific populations of adults and adolescents who meet established body mass index (BMI) criteria. Under the brand name Wegovy, it is currently approved for the following groups:

Adults and adolescents aged 12 and older who are classified as obese.

Adults who are classified as overweight and have at least one weight-related health condition.

In some cases, Semaglutide may be prescribed off-label for individuals who do not meet these criteria. This off-label use means that the FDA has not officially confirmed the safety and efficacy of Semaglutide for these specific purposes.

Nevertheless, your healthcare provider may determine that Semaglutide is an appropriate treatment option for you based on your individual health needs.

WHAT IS THE SEMAGLUTIDE DOSAGE FOR WEIGHT LOSS?

Semaglutide is administered as a once-weekly injection, typically on the same day each week, and can be given at any time of day, regardless of meals. Treatment usually begins with a low dose, gradually increasing every 4 weeks until the target maintenance dose of 2.5 mg once weekly is reached. If the 2.5 mg dose is not well tolerated, your healthcare provider may adjust your maintenance dose to 1.5 mg weekly.
This dosing schedule is designed to help manage potential side effects. If you experience difficulty tolerating Semaglutide, your prescriber may reduce the dose or advise discontinuation of the medication.

SEMAGLUTIDE DOSAGE SCHEDULE

The starting Semaglutide dose for adults and children aged 12 and up is 0.25 mg once weekly for 4 weeks. If tolerated, the dose increases every 4 weeks until reaching the target maintenance dose of 2.4 mg once weekly for Wegovy.

A typical dosing schedule is as follows:

Month 1: 0.25 mg once weekly
Month 2: 0.5 mg once weekly
Month 3: 1 mg once weekly
Month 4: 1.5 mg once weekly
Month 5 and beyond: 2.5 mg once weekly (maintenance dose)

(The gradual dose increase helps minimize digestion-related side effects. If you struggle with a dose increase, your healthcare provider may delay the next step by 4 weeks)

**Note: If the 2.5 mg dose cannot be maintained, even after a temporary reduction, you may need to discontinue Semaglutide. For children aged 12 and older, a long-term dose of 1.5 mg once weekly may be appropriate**

HOW TO INJECT SEMAGLUTIDE

Semaglutide should be injected subcutaneously, just under the skin. Suitable injection sites include the abdomen, upper arm, or thigh. It’s important to rotate your injection site with each dose to minimize the risk of injection site reactions. Avoid using the same spot repeatedly to help maintain comfort and effectiveness.

SIDE EFFECTS OF SEMAGLUTIDE

Gastrointestinal issues are the most commonly reported side effects when using Semaglutide for weight loss. These symptoms are often more noticeable when beginning treatment or after increasing the dose. Common side effects include:

Nausea and vomiting
Diarrhea
Abdominal pain
Constipation
Headaches
Fatigue

Although rare, Semaglutide has been linked to some serious side effects, such as:

Inflammation of the pancreas (pancreatitis)
Problems with the gallbladder
Kidney injury
Low blood sugar levels (hypoglycemia)
Increased heart rate
Worsening of diabetic eye conditions
Higher risk of thyroid C-cell tumors

DOSAGE ADJUSTMENTS FOR MEDICAL CONDITIONS?

There are no specific dosage adjustments recommended for Semaglutide in individuals with kidney or liver conditions. However, there have been reports of kidney function deterioration during treatment. If you have existing kidney issues, your healthcare provider may choose to monitor your kidney function more closely throughout your treatment.

Semaglutide may cause gastrointestinal side effects, such as severe or persistent nausea, vomiting, and diarrhea, which can lead to significant fluid loss. It is important to inform your healthcare provider if you experience these symptoms. Excessive fluid loss can result in dehydration, potentially exacerbating kidney function and leading to other complications.

MISSED A DOSE OF SEMAGLUTIDE?

While it's important to follow your prescribed dosing schedule, it's understandable that you may occasionally miss a dose. If you realize you've missed a dose of Semaglutide and your next scheduled dose is more than 48 hours away, take the missed dose as soon as you remember. However, if your next dose is within 48 hours, skip the missed dose and continue with your regular dosing schedule.

It's crucial not to administer two doses of Semaglutide within 48 hours, as this could lead to an excessive amount of the medication in your system, increasing the risk of side effects.

If you miss your Semaglutide dose for more than two weeks, you can either take your next dose on the usual day or consult your healthcare provider for guidance on restarting the medication. Your pharmacist can also offer helpful strategies for remembering to take your medication regularly.

TOOK TOO MUCH OF SEMAGLUTIDE?

If you accidentally take an excessive dose of Semaglutide, you may experience symptoms such as nausea, vomiting, diarrhea, bloating, and a decreased appetite.

While standard doses of Semaglutide generally do not cause hypoglycemia (low blood sugar), the risk may increase if you are using it alongside other diabetes medications. If you take too much Semaglutide, it’s important to monitor for signs of hypoglycemia, including shaking, nausea, and a rapid heartbeat.

If you believe you have taken an excessive amount of Semaglutide, contact your healthcare provider or reach out to Poison Control at 1-800-222-1222 for advice. If any symptoms are severe or potentially life-threatening, seek immediate medical attention at the nearest emergency room.

TIRZEPATIDE vs. SEMAGLUTIDE

Tirzepatide, a once-weekly injection, was approved in November 2023 for weight loss in adults. It is also marketed under the brand name Mounjaro for the treatment of Type 2 diabetes in adults.

Similar to Semaglutide, Tirzepatide mimics the action of GLP-1, but it also mimics another incretin hormone called glucose-dependent insulinotropic polypeptide (GIP). While Tirzepatide shares many effects with Semaglutide, it is unique as the first and only medication in its class. However, it has not yet been approved for the same cardiovascular benefits as Semaglutide.

In the largest clinical trial for Tirzepatide focused on weight loss, participants receiving the medication experienced an average reduction of 15% to 21% of their starting body weight. This was significantly higher compared to the 3% weight loss observed in those receiving a placebo. Therefore, Tirzepatide may offer the potential for greater weight loss than Semaglutide.

WHAT IS SEMAGLUTIDE?

SIDE EFFECTS OF SEMAGLUTIDE

TIRZEPATIDE vs. SEMAGLUTIDE

This website uses cookies.